A Benchmark Research analyst expects that the Food and Drug Administration will allow Inovio Pharmaceuticals Inc.'s (INO) COVID-19 vaccine candidate to move to a Phase 2/3 study. Benchmark's Aydin Huseynov noted that while the Phase 1 efficacy data provided by Inovio (http://www.marketwatch.com/story/inovios-stock-falls-as-it-discloses-early-stage-data-for-its-covid-19-vaccine-candidate-2020-06-30) before the market opened on Tuesday morning was "insufficient to make a judgment call about the future utility of the vaccine," he is still encouraged by the news. He reiterated a buy rating. The company's stock was down 23.7% in trading on Tuesday. Since the start of the year, Inovio's stock has soared 628.3%, while the S&P 500 is down 5.5%.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.